Cargando…

Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer

Cancer survival rates are generally increasing in the United States. These trends have been partially attributed to improvement in therapeutic strategies. Cancer immunotherapy is an example of one of the newer strategies used to fight cancer, which primes or activates the immune system to produce an...

Descripción completa

Detalles Bibliográficos
Autores principales: Dine, Jennifer, Gordon, RuthAnn, Shames, Yelena, Kasler, Mary Kate, Barton-Burke, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412150/
https://www.ncbi.nlm.nih.gov/pubmed/28503645
http://dx.doi.org/10.4103/apjon.apjon_4_17
_version_ 1783232929817690112
author Dine, Jennifer
Gordon, RuthAnn
Shames, Yelena
Kasler, Mary Kate
Barton-Burke, Margaret
author_facet Dine, Jennifer
Gordon, RuthAnn
Shames, Yelena
Kasler, Mary Kate
Barton-Burke, Margaret
author_sort Dine, Jennifer
collection PubMed
description Cancer survival rates are generally increasing in the United States. These trends have been partially attributed to improvement in therapeutic strategies. Cancer immunotherapy is an example of one of the newer strategies used to fight cancer, which primes or activates the immune system to produce antitumor effects. The first half of this review paper concisely describes the cell mechanisms that control antitumor immunity and the major immunotherapeutic strategies developed to target these mechanisms. The second half of the review discusses in greater depth immune checkpoint inhibitors that have recently demonstrated tremendous promise for the treatment of diverse solid tumor types, including melanoma, non-small cell lung cancer, and others. More specifically, the mechanisms of action, side effects, and patient and family management and education concerns are discussed to provide oncology nurses up-to-date information relevant to caring for cancer-affected patients treated with immune checkpoint inhibitors. Future directions for cancer immunotherapy are considered.
format Online
Article
Text
id pubmed-5412150
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-54121502017-05-12 Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer Dine, Jennifer Gordon, RuthAnn Shames, Yelena Kasler, Mary Kate Barton-Burke, Margaret Asia Pac J Oncol Nurs Review Article Cancer survival rates are generally increasing in the United States. These trends have been partially attributed to improvement in therapeutic strategies. Cancer immunotherapy is an example of one of the newer strategies used to fight cancer, which primes or activates the immune system to produce antitumor effects. The first half of this review paper concisely describes the cell mechanisms that control antitumor immunity and the major immunotherapeutic strategies developed to target these mechanisms. The second half of the review discusses in greater depth immune checkpoint inhibitors that have recently demonstrated tremendous promise for the treatment of diverse solid tumor types, including melanoma, non-small cell lung cancer, and others. More specifically, the mechanisms of action, side effects, and patient and family management and education concerns are discussed to provide oncology nurses up-to-date information relevant to caring for cancer-affected patients treated with immune checkpoint inhibitors. Future directions for cancer immunotherapy are considered. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5412150/ /pubmed/28503645 http://dx.doi.org/10.4103/apjon.apjon_4_17 Text en Copyright: © 2016 Ann & Joshua Medical Publishing Co. Ltd http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Review Article
Dine, Jennifer
Gordon, RuthAnn
Shames, Yelena
Kasler, Mary Kate
Barton-Burke, Margaret
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
title Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
title_full Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
title_fullStr Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
title_full_unstemmed Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
title_short Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
title_sort immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412150/
https://www.ncbi.nlm.nih.gov/pubmed/28503645
http://dx.doi.org/10.4103/apjon.apjon_4_17
work_keys_str_mv AT dinejennifer immunecheckpointinhibitorsaninnovationinimmunotherapyforthetreatmentandmanagementofpatientswithcancer
AT gordonruthann immunecheckpointinhibitorsaninnovationinimmunotherapyforthetreatmentandmanagementofpatientswithcancer
AT shamesyelena immunecheckpointinhibitorsaninnovationinimmunotherapyforthetreatmentandmanagementofpatientswithcancer
AT kaslermarykate immunecheckpointinhibitorsaninnovationinimmunotherapyforthetreatmentandmanagementofpatientswithcancer
AT bartonburkemargaret immunecheckpointinhibitorsaninnovationinimmunotherapyforthetreatmentandmanagementofpatientswithcancer